TP53 and Li-Fraumeni syndrome: In the specific biological context of Li-Fraumeni syndrome and medulloblastoma, TP53 mutations have been associated with chromothripisis, an event characterized by massive genomic rearrangements, causing genomic instability [30], which may be an important evolutionary driver of metastatic ability or chemotherapy treatment resistance [39].